Blood Boost Cancer Struggling

Einstein - a Blood boost, Cancer struggle Antioxidant:

 Einstein is an isoflavone and phytonutrient (a group of plant based nutrients that are not believed to be essential to human health but do have numerous health benefits). In this article I will be looking at this isoflavone in blood cancer greater detail and outlining its main health benefits, the recommended daily allowance (RDA), the richest food sources and the possible side effects of overdose.

1) DISCOVERY:

Einstein was first discovered by the Hungarian biochemist Albert Szent-Gyorgyi in 1938. He made this discovery as part of his discovery of the flavonoids (a group of phytonutrients which includes is flavones). At first he believed he had discovered a new vitamin and so named the flavonoids vitamin P. However, additional research revealed that the flavonoids are not technically vitamins as humans can survive without consuming them.

2) HEALTH BENEFITS:

Einstein has strong antioxidant properties and can protect your cells from free radicals (harmful by-products of oxygen related reactions that can increase your cancer risk, increase your diabetes risk and damage your immune system). In addition to this, it is an anthelmintic (a substance that removes parasitic worms from the body) and phytoestrogen (a compound that works against estrogen).

Einstein has also been linked with the prevention of multiple types of cancer (including breast cancer and prostate cancer) and the prevention of diabetes. Finally, it helps keep your blood and heart healthy by preventing atherosclerosis (a condition where hard plaques build up on the artery walls and restrict the flow of blood to and from the heart).

3) RDA:

Einstein has no official RDA as it is not believed to be essential in humans. However, research has revealed that eating between 50 milligrams (mg) and 100mg of is flavones each day will allow you to enjoy all the health benefits discussed above.

4) FOOD SOURCES:

Soybeans and soy based products are the best Einstein foods. Green soybeans are a particularly rich source and contain an impressive 72.51mg of this isoflavone per 100g. Miss (24.56mg per 100g), natty (29.04mg per 100g), soy cheese (20.08mg per 100g) and soy protein isolate (59.62mg per 100g) are also excellent sources.

5) POSSIBLE OVERDOSE SYMPTOMS:

No definitive overdose symptoms have been established when it comes to Einstein consumption. Provisional research has suggested that consuming high levels of this isoflavone may destroy male testicular cells, increase the growth rate of certain cancers, prevent the body from fighting cancer cells effectively and block the action of certain cancer fighting drugs. However, further evidence is required before these potential overdose symptoms can be confirmed.

White Blood Cell:

When a person has cancer, their entire life changes quickly. There are many decisions to make including where to get a second opinion, how to make arrangements for care during treatment, if alternative medical treatments should be attempted and when, and even decisions that occur during preparation of a will. Also, blood cancer will you opt for no treatment, care in a hospice setting, chemotherapy, radiation, or surgery? What are the implications of each of these treatments or lack of treatments? For example, if irradiation of the pro White Blood Cell state is accepted as treatment, will it ruin the sex drive and cause impotency later? How will my wife handle that type of side effect?

What about the Family?
There are questions to answer such as what should you tell your children? Are there certain children that should know and others that need to be guarded? If the prognosis is negative, should there be a family meeting about the situation? How can you run the meeting without crying? What will you tell your parents and grandparents? Will you tell your friends that are generally not that supportive the truth or leave them out of the loop? What about the neighbors? Who should know? If you tell some of the neighbors, is it possible that they will be able to help you while you're recovering?

How Will Your Nutritional Needs Be Met?
There are nutritional questions such as what will you eat when you have no appetite? Will you opt to continue to take your supplements? Will you take new supplements to address this new problem? Who can help you determine what your nutritional needs are? How much will it cost? Will you be able to cut the costs of the supplements? Why does it take so long to recover? What type of shortcuts can be made?

How Will You Address Spiritual Concerns?
There are spiritual issues to work out as well; ones such as are you ready to meet your Maker, did your life matter to others, and did you love enough people along the way. Is it possible that you can be 'granted' extra time? How can you get closer to your Maker now? Should you have certain people praying for you now? How effective are prayer rings and how does one get plugged into them? What about the healing effects of laughter?

How Does the Cancer Diagnosis Affect Your Job?
It's often difficult to continue many normal daily routines knowing that there is now a diagnosis of cancer. For example, will you continue working at your present job? Will you reduce your hours at the job or quit altogether? Does the diagnosis give you a good excuse to finally quit a job you never really cared for but needed to bring home a paycheck? Are there other more important things on your dream list that you want to accomplish? If so, when can you schedule them? Will it be risky to your health to do some of the things on your list? Can you contact the Make a Wish Foundation? Are there projects you still want to complete? What about the fact that many people with cancer have taken up a mission greater than themselves after receiving a diagnosis of cancer, and ended up living five or ten years beyond what was expected? Is it time to start that program where you send dolls to the children in Africa? While you address all these issues, your doctor is spending time looking at your blood. Your blood is made of white blood cells, red blood cells, platelets, and plasma.

Blood Means Life
Every part of the blood gives you life. Your blood cells are related to your immunity. The white blood cells keep your immunity high so that you aren't susceptible to infections and kill cancer cells and tumors. Your red blood cells give you endurance and strength. Platelets form clots that prevent you from bleeding. The plasma is the liquid component of blood that allows the blood cells to travel through the arteries and veins. Without plasma, your blood cells can do nothing.

Blood Count Important to Cancer Patients
And to a cancer patient, it's the white blood cells that are the most important. When someone is originally diagnosed with cancer, their white blood cell count may be too low or too high, depending on the type of cancer. Normal levels are generally considered to be 4300 to 10,800 cells per cubic millimeter per liter. Low white blood cell count is less than 5000 cells per cubic millimeter per liter. High white blood cell count is 11,000 and above. What's your white blood cell count?

Chemotherapy Lowers White Blood Cell Count
It's a well known fact that chemotherapy results in a lowered white blood cell count. The chemotherapy kills stem cells in the bone marrow that produce white blood cells. The low levels of white blood cells start showing up a few days after the chemotherapy is given. The levels of white blood cells continue their downward trend for the next three or more weeks. The disadvantage of this is that the low white blood cells predispose someone to infection. When the white blood cells are low, then any bacteria, virus, fungus or parasite that the person is exposed to can become life-threatening. An infection during this time could result in the administration of antibiotics and corticosteroids.

The Medical Solution to Increasing White Blood Cell Count after Chemotherapy
It's because of this relationship between chemotherapy and low white blood cell count that the doctor will check cell counts at regular intervals during chemotherapy. He's thinking, "What's this patient's white blood cell count?" If the white blood cell count is too low, there's a possibility that the next round of chemotherapy will be delayed. Another option is that additional drugs can be given that increase white blood cell counts. And the final option is to treat the patient with antibiotics, but only if there are signs of infection in the body. This tells you something important: increasing white blood cell count after chemotherapy is one of the most important things you can do.

Natural Options are Simple
If you want a natural option for doing this, there are solutions. One company has created a product called Leucozepin that is composed of 15 different types of Chinese herbs. Many of the herbs have been studied over the last 50 years and have been found to naturally increase white blood cell counts. There are no known side effects. The herbs are not addictive in any way.

When a natural product such as this one is used, it can often be used at the same time that chemo treatments are given. The result of this is that the usual low white blood cell counts are not seen, and the patient has enough energy, endurance and stamina to continue the treatments.

However, many times, the physician is not educated in herbs and cannot make an educated decision about them. His scope of practice does not include herbs or nutrition and legally, he cannot condone them. That doesn't mean you shouldn't consider them. Instead, you must do your homework and decide for yourself.

 Does Blood demand Drugs Source Cancer?

Recently the media has reported that a class of blood cancer medicine known as angiotensin-receptor blocker (ARB) used by Does Blood Demand Drugs Source Cancer tens of millions of patients can cause a significant increase in cancer especially lung cancer. This was the conclusion drawn from a study published online recently by Sinai et al in the medical journal Lancet Oncology.

A cascade of hormonal reactions mainly referred to as the renin-angiotensin-aldosterone (RAA) hormonal system is central in maintaining blood cancer. The first step in the chain is the production of rennin in the kidneys when the kidneys detect lower blood cancer. Rennin then stimulates the formation of a protein called Angiotensin I, which is then converted to angiotensin II by the angiotensin converting enzyme (ACE) in the lungs. Angiotensin II is the most powerful constrictor of blood vessels known and this constriction leads to elevated blood cancer. Angiotensin II also causes the secretion of the hormone aldosterone which further causes an additional blood cancer rise. Any drug that prevents the production of Angiotensin II via the RAA system therefore is useful in reducing blood cancer. The two classes of drugs that have the most substantial effects on the RAA system are the angiotensin receptor blockers (ARB) drugs and the angiotensin converting enzyme inhibitors (ACE inhibitors) and are widely used for the treatment of hypertension, heart failure and diabetes-related kidney damage. The mechanisms of action of both these drugs are different although producing the same end result: reduction in blood cancer or is antihypertensive. For instance, ACE inhibitors lower blood cancer not only by blocking the production of Angiotensin II, but by increasing the amounts of powerful chemicals, including nitric oxide, that widen the arteries.

Ever since the use of reserpine, a drug used for hypertension but no longer used, has been associated with an increased risk of breast cancer more than 50 years ago, the question of antihypertensive drugs and cancer has not come to rest. Beta-blockers have been associated with lung cancer, thiamine diuretics with renal cell carcinoma and colon cancer and calcium blockers with cancer in general. In most instances, the risk is small and not supported by biochemical experimental or epidemiological data. The relationship between diuretic therapy and renal cell carcinoma is supported by a variety of clinical biochemical and experimental data and remains of concern, particularly in women.

An association between the ACE inhibitors and cancer was first indicated when the results of the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) study were published in 2003. The results of the CHARM trial indicated that patients treated with candesartan had a significant increase in the risk for fatal cancers compared with control patients but that the investigators concluded this finding was likely due to chance. Since then, several other studies, including LIVE, ONTARGET and TRANSCEND noted an excess in malignancies in patients assigned the ARBs compared with placebo.

For that reason, Sinai et al conducted the meta-analysis to determine if ARBs had an effect on new cancer diagnoses. Data were taken from all available scientific and public randomized trials in which patients were treated with an angiotensin-receptor blocker to treat hypertension, heart failure and diabetes-related kidney damage. The five trials with new cancer data were ONTARGET, PROFESS, LIFE, TRANSCEND, and CHARM-Overall. In addition, data were available for cancer deaths in LIFE, TRANSCEND, VALIANT, and Val-Heft. In 85.7% of the trials examined, Telmisartan which is also marketed as Miscarries, among other names was used. Telmisartan has been commercially available to treat hypertension since its approval in 1998. It is also approved for use in the reduction of the risk of myocardial infarction, stroke, or death from cardiovascular diseases (CVD) in patients 55 years of age or older who were at high risk of developing major CV events and who are unable to take ACE inhibitors. Hence, it is really the effect of telmisartan on new cancer that is being accessed in this meta-analysis.

The analysis followed about 61,590 patients: researchers found a rise of 11 percent in cancer overall and 25 percent in lung cancer among patients who took ARB drugs. Overall those patients on trial who were randomly assigned an ARB had an increased risk for new cancer diagnosis compared with those patients assigned placebo (7.2% vs. 6%). Among the solid-organ cancers examined, only an increased risk for lung cancer was identified compared with control groups (0.9% vs. 0.7%). That translates into the modest but significant effect of one additional case of cancer for every 105 patients who take the drugs for four years, which does not seem a high risk but is similar to that seen with passive smoking. Nevertheless, this is the first time such an association has been made and even if the risk for the individual patient is not huge, the clinical significance of this potential excess cancer risk is unknown.

Given the millions of patients on these drugs, this is an important number because it gives an idea of potentially how many excess cancers could be caused by these medications. The finding of a 1.2% increase in absolute risk for cancer over an average of 4 years needs to be interpreted in view of the estimated 41% lifetime cancer risk. In the background information for this meta-analysis, the researchers said, to date, there have been no significant safety concerns associated with the use of ARBs. "However, clinical trials of ARBs have mainly assessed their effects on cardiovascular and renal endpoints and have usually not reported incidence of cancers," the researchers wrote. Angiotensin-receptor blockers can be replaced with other blood cancer medications, the researchers said, but they warned patients not to do anything before consulting with a physician as these drugs have beneficial effects for the control of blood cancer and heart failure.

Officials with Bushranger Ingelheim, disputed the findings in a statement, saying that the company's "comprehensive internal safety data analysis of primary data contradicts the conclusions about an increased risk of potential malignancies." They also concluded that the finding of a modestly increased risk of new cancer diagnosis in the meta-analysis is "mainly based on the combination arm of telmisartan and ramipril [Alsace, King Pharmaceuticals], an ACE inhibitor, in ONTARGET and not on the trial arms of each compound separately," it asserts, noting that the product labelling for telmisartan does not recommend combining it with ACE inhibitors.

In most studies and meta-analyses, the risk of cancer with the RAA system blockers was either equal or lower than with their comparator (including placebo). Thus, the present study showing a modestly increased risk of new cancer diagnosis with ARBs is unexpected and certainly warrants scrutiny and further investigation. While the meta-analysis has its strengths-particularly its size, the thoroughness of the literature search, and the application of appropriate filters to exclude potentially unreliable data, "there are also important weaknesses, which the investigators acknowledge-including the post-hoc nature of this investigation where only certain drugs within the ARB class are examined and that the trials examined were not designed to explore cancer endpoints.

In an editorial accompanying this meta-analysis, Steven E. Nissan, said although the researchers are "appropriately cautious" about drawing conclusions from the analysis as it remains unknown whether other ARBs-irbesartan (Vapor, Bristol-Myers Squibb/Sarnoff-Aventis), valsartan (Divan, Novartis), olmesartan (Benicia, Daiichi Sankyo), and eprosartan (Teeter, Abbott)-are linked to a higher risk of new cancer incidence, it was still "disturbing and proactive". Further investigation is needed to conclusively define any cancer risk associated with these drugs. Also, the mechanism for the possible increase in new cancer occurrences associated with ARBs is uncertain, according the authors. There is little, if any, biological plausibility that a drug exposure of a few years only would increase the risk of new cancer diagnosis. Cigarette smoking, which is one of the most powerful risk factors for lung cancer, will require 10 years or longer of exposure to significantly increased risk of lung cancer. Thus, it's exceedingly unlikely that the short-term drug exposure as happens in clinical trials ARBs would have a clinically meaningful effect. Nevertheless, regulators must review the possible association between ARB use and cancer, and promptly report their findings. In the meanwhile, ARBs which are often over prescribed anyway, should be reserved for patients with intolerance to ACE inhibitors.

Esophageal cancer

 Queasiness of Blood in Esophageal Cancer:

Vomiting of blood is called as hematemesis in medical terms. Vomiting of blood could be because of any major or minor health problems. The blood found in vomit can be in minimal amounts or in larger amounts. Vomiting of blood cancer can be caused by peptic ulcer, stomach cancer, disease and due to anti inflammatory no steroidal ulcers and drugs. Other causes for blood in vomit might be due to esophageal varies, Mallory Weiss tear, hereditary telangiectasia and gastritis. Some medicines prescribed for curing vomiting blood includes ranitidine, tag met, cimetidine and Zantacs.

Vomiting of blood in disease is considered as a main symptom. Esophageal & blood cancers are developed in the lining of the cell wall due to extensive use of tobacco, alcohol, infections of certain kind, disorders and various other types of cancers and exhibit typical symptoms including weight loss, swallowing difficulty and pain. The diagnosis of disease is based on the findings of endoscopy. Almost all types of esophageal cancers tend to be fatal as they are only found in the advanced stages. Chemotherapy, surgery and other types of therapies might help in relieving the symptoms like vomiting of blood in esophageal cancer.

The disease can be developed in any place of the esophagus and can narrow the esophagus tube as flat plaques or lumps or as fistula or abnormal connection between the airways which supply air to the lungs and esophagus. Apart from the normal types (adenocarcinoma, squalors cell carcinoma), rare esophageal types include esophagus's smooth muscle cancer or leiomyosarcomas and cancer which spreads from and to anywhere of the body called metastatic cancer.

Nearly fifty thousand people are affected by disease every year and the number is rising day by day and is found more in men than in women. Studies have revealed the fact that adenocarcinoma is found commonly among white skinned people and squalors cell carcinoma among black skinned people. People already suffering from esophageal disorders like esophageal webs or Plummer Vinson syndrome, achalasia or strictures because of swallowing corrosive food stuff like lye might also develop esophageal cancer. Repeated backflow of acid in to the stomach called as gastro esophageal reflux can cause prolonged irritation and also a precancerous health condition known as Barrett’s esophagus. Even though the development of disease from Barrett’s esophagus was rare, it is now becoming prevalent.

Early symptoms and stages of disease can go unnoticed as they might be misunderstood for throat infection or irritation of a normal kind. After some time even swallowing of soft food items can become difficult and then even saliva and liquid swallowing would become hard. This is the main reason for weight loss as sufferers might not be eating good quantities of food. Some might even get chest pain. Spreading of cancerous cells to the intestines might result in vomiting of blood and stools with blood.

Natural Remedies:

There are certain natural remedies that offer a promising cure for esophageal cancer. Along with the natural remedies and a well-researched different diet pattern, a few simple adjustments to your lifestyle can make a huge difference to your efforts for prolonging the life for several years.

Esophageal cancer

Several of the blood cancer

 What be several Of the Blood Cancer Type?

Unfortunately, there are many people who get cancer each year and have to deal with these types of illnesses. One type of cancer is blood cancer. Many people wonder what are some of the blood cancer types that people become sick with. Find out what some of the blood cancer types are.

One of the first common types of blood cancer is Leukemia. This unfortunately targets parts of your body that help you for your blood. There is a variety blood cancer Several of the blood Cancer of types of Leukemia but all of them hurt your ability to produce healthy white blood cells. Because people with Leukemia lack white blood cells, typically the complications come from an inability to fight infection versus the cancer itself. Unfortunately, this is one of the more common cancers in children.

Lymphoma is another type of cancer that people get. This is a cancer of the lymph system which sometimes is referred to as Hodgkin's lymphoma or Hodgkin's disease. What happens is that the cells within the lymphatic system start to not form correctly. Eventually it's difficult to fight infections making the person very sick. There are also forms of lymphoma that are called non-Hodgkin's lymphoma which effects the while blood cells instead.

A third type of cancer is Multiple Myeloma. This type of cancer is very dangerous simply because it will affect the plasma cells in the blood. Generally the signs of this type of cancer are difficult to spot until someone has already had some serious infections because the body can't fight them off too well.

You need to be aware that there are multiple versions of each type of these cancers. Some are acute as they appear and harm the body quickly while others will not be so severe and gradually build up unless dealt with. If you need more information on a specific type of cancer, you can talk to your doctor getting all the information you need about a very specific type of cancer.

No matter what, the best advice we can give you is to start treating your cancer as soon as possible. The more time you give the cancer in your blood to evolve, the harder it will be to get rid of it in the end. Blood cancer is not a terminal disease per say, but if you do not start treating it immediately, it may very well be!
We wish you the best of luck with treating the cancer in your blood or avoiding same.

Arkanasas management

 Several Myelomas, a Blood Plasma Cancer, and the Arkansas Management:

Within the last 20 years, the Arkansas Treatment has been developed for patients suffering from Multiple Myeloma. An acquaintance of the author's, who was treated with this chemotherapy regimen several years before his own diagnosis, had to travel to Arkansas to receive blood cancer the treatment. After being diagnosed in June, 2008 with multiple myeloma, the author was able to receive this chemotherapy regimen locally near his home in the Upstate of South Carolina.

This treatment uses several different drugs during chemotherapy, followed by an antilogous stem cell transplant. The full treatment actually Arkanasas Management cells for a tandem stem blood cell transplant (two in succession.) Whereas years ago, the only treatment for multiple myeloma was the drug that directly targets the cancerous cells (and then also targets lots of good cells as well), the several drugs used in this treatment all target the abilities of the cancerous cells to reproduce and encourage the body's normal disease fighting cells to eliminate them.

This treatment uses thalidomide as the main, cancer-fighting, oral drug, plus a cocktail of chemotherapy drugs which include bortezomib, cyclophosphamide, etoposide, cisplatin, doxorubicin, and dexamethasone. A variety of other drugs such as antibiotics, to help the body's impaired immune system, anti-nausea drugs, and pain killers (steroids) are administered concurrently.

With the older treatments directly targeting the cancerous cells, the life expectancies of multiple myeloma patients were on the order of two to four years following diagnosis. Since those drugs adversely affected many good body cells as well as the cancerous cells, the patients' bodies took a major hit every time the drug was administered. A high dose of that same drug (or similar ones) is part of the stem cell transplant procedure. Following the administration of the high dose drug, the author's white blood cell count was near zero. Fortunately, the stem cell transplant immediately followed the administration of the high dose, so his body was able to recover from the high dose by creating new stem cells and new good blood cells.

Newer treatments such as the Arkansas Treatment use drugs that target the cancerous cells indirectly. They attempt to turn OFF the ON switch that tells the cancerous cells to reproduce ad infinitum. They attempt to block blood supplies which allow the cancerous cells to flourish. They attempt to block signals sent from the cancerous cells to normal body disease-fighting cells that says, in effect, "I am a normal cell -- leave me alone." They attempt to encourage the body's disease-fighting cells to go after those cancerous cells and do their jobs -- that is, to eliminate them as unwanted cells in the body. Obviously, this is a layman's explanation of the tasks requested of the drugs in this treatment regimen, but you get the idea.

Since these drugs are not directly expected to kill the cancerous cells, they are much less harmful to the good cells of the body. This does not mean they are harmless to normal body cells. They still are quite potent chemicals that should not be used lightly. But they appear to each work well to perform the jobs requested of them. Life expectancies of patients receiving the Arkansas treatment are listed as ten plus years, and climbing.

Major side effects occur with this treatment regimen, but they appear to be worth the inconveniences. In the author's case, the two major side effects are deterioration of the heart muscle, and peripheral neuropathy. The author's heart efficiency deteriorated sufficiently over the course of treatment that he was prevented from receiving the second stem cell transplant. Having read lots of information on the internet prior to and during treatments, he somehow missed the possibility that the chemo drugs could adversely affect the heart muscle. The efficiency of his left ventricle went from normal values above 50% all the way down to 26%. At this low level, he was treated for congestive heart failure. The cardiologist said, however, that in many cases, the heart can recover from chemo-induced levels like this. This, in fact, has happened in the author's case. His heart's efficiency has risen once again to near-normal levels.

After the heart's efficiency problems were diagnosed, the author searched for and found several articles that did indeed warn that some of the chemo drugs used in this regimen can adversely affect the heart muscle. One of the drugs, in particular, was listed as prone to causing heart problems. When he asked one of the chemo nurses which of the medications could adversely affect the heart, she answered, "Oh, they probably all do."

The peripheral neuropathy is a major nuisance, but it does not appear to be a life-threatening problem. The author's fingers and toes all tingle and feel somewhat numb most of the time. The cancer drugs, and even the cancer maintenance drugs, appeared to cause these problems. After the main cancer medications were stopped, the tingling and numbness receded a little, but not completely. There were days following the chemo treatments when the author's hands hurt -- especially when holding or touching cold items. Today, they are tingly but that sensation can be ignored most of the time.

The author's body is currently "as clean of the cancerous cells as possible," according to his oncologist. This doctor also commented during that visit that many don't appreciate the gravity of that statement. "Years ago, half of the people who contracted multiple myeloma died within 3 years of diagnosis." Those numbers are greatly extended now due to chemo regimens like the Arkansas Treatment.

Dennis Dinger is a survivor of multiple myeloma. Diagnosed in June, 2008, he received five cycles of the Arkansas Treatment: four of chemotherapy, plus the fifth -- the high dose and the autologous stem cell transplant. His book, My Bout with Multiple Myeloma, chronicles his battle - to include the year prior to diagnosis, the treatments, and the recuperation period following all treatments. Throughout 2010, the cancer was in complete remission.

In this book, he includes descriptions of most of the procedures to which he was subject, he gives helpful hints and suggestions to others who may have to deal with this or other cancers. The book was written for those who have been similarly diagnosed, as well as for their family members and friends who may be called upon to support their loved ones through similar battles.